All In Biotech

BLA 761041 · Genentech INC

Tecentriq

Atezolizumab · Injection

Breakthrough therapyPriority review

Last checked: Nov 20, 2026Latest source record: Oct 18, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Oct 18, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

858

134 Phase 3, 179 recruiting

FAERS reports

39,719

37,952 serious, 10,079 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 18, 2016 Original approval · Type 9 - New indication submitted as distinct BLA, consolidated · priority review Breakthrough therapyLabelLetterMedication Guide
1 products under this application
  • TECENTRIQ · ATEZOLIZUMAB 1200MG/20ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Atezolizumab" as an intervention, any sponsor and status, largest first.

All 858 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death4,361
  • off label use3,721
  • disease progression2,260
  • pyrexia1,803
  • diarrhoea1,750
  • fatigue1,560
  • anaemia1,387
  • pneumonia1,160
  • decreased appetite1,143
  • hypothyroidism1,132
  • nausea1,095
  • dyspnoea1,061

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20111
20121
20143
201525
2016603
20171,159
20181,889
20192,604
20203,354
20215,267
20225,804
20235,878
20245,155
20254,659
20263,317

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tecentriq (Atezolizumab)

2024 spending

$23.0M

Beneficiaries

410

2,145 claims

Per beneficiary

$56,037

$522.51 per unit

View as table
YearSpending
2020$12,942,335
2021$14,535,133
2022$24,590,543
2023$28,732,491
2024$22,975,155

Part B: Tecentriq (Atezolizumab) · HCPCS J9022

2024 spending

$678M

Beneficiaries

10,191

63,083 claims

Per beneficiary

$66,497

2024 ASP limit $85.24 per unit

View as table
YearSpending
2020$624,194,084
2021$656,074,899
2022$777,758,575
2023$755,223,832
2024$677,665,952

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 815 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.